{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:22:36Z","timestamp":1785792156011,"version":"3.56.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113455","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T04:37:42Z","timestamp":1700800662000},"page":"113455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9998-7463","authenticated-orcid":false,"given":"Alimu","family":"Dayimu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeta N.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-5983","authenticated-orcid":false,"given":"Jenny","family":"Nobes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Board","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Carser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara O\u2019Hanlon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Highley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2080-4749","authenticated-orcid":false,"given":"Ashita","family":"Waterston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-8194","authenticated-orcid":false,"given":"George","family":"Burghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Demain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0071-4970","authenticated-orcid":false,"given":"Jerome","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-2925","authenticated-orcid":false,"given":"Sophie","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-7021","authenticated-orcid":false,"given":"Pippa","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2023.113455_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2023.113455_bib2","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.ejca.2023.113455_bib3","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [published correction appears in J Clin Oncol. 2023 Apr 20;41(12):2301]","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7377","key":"10.1016\/j.ejca.2023.113455_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2023.113455_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-11-0997","article-title":"BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance","volume":"18","author":"Alcal\u00e1","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7436","key":"10.1016\/j.ejca.2023.113455_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2023.113455_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","article-title":"Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor","volume":"22","author":"Seghers","year":"2012","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.ejca.2023.113455_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1758834014548187","article-title":"Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series","volume":"6","author":"Dooley","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113455_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","article-title":"Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial","volume":"26","author":"Algazi","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2023.113455_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26572-6","article-title":"Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial","volume":"12","author":"Gonzalez-Cao","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2023.113455_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/17423953211060253","article-title":"Burden of cancer trial participation: a qualitative sub-study of the INTERIM feasibility RCT","volume":"19","author":"Nwolise","year":"2023","journal-title":"Chronic Illn"},{"issue":"2","key":"10.1016\/j.ejca.2023.113455_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000948","article-title":"Evolving impact of long-term survival results on metastatic melanoma treatment","volume":"8","author":"Michielin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"34","key":"10.1016\/j.ejca.2023.113455_bib13","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.20.01382","article-title":"Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors","volume":"38","author":"Piccart","year":"2020","journal-title":"J Clin Oncol"},{"issue":"548","key":"10.1016\/j.ejca.2023.113455_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8084","article-title":"ctDNA monitoring using patient-specific sequencing and integration of variant reads","volume":"12","author":"Wan","year":"2020","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.ejca.2023.113455_bib15","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.3390\/cancers13246217","article-title":"Methylation markers in cutaneous melanoma: unravelling the potential utility of their tracking by liquid biopsy","volume":"13","author":"Aleotti","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2023.113455_bib16","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/cancers12102801","article-title":"Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ejca.2023.113455_bib17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300758X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300758X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:13Z","timestamp":1760733793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300758X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":17,"alternative-id":["S095980492300758X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113455","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113455"}}